Jupiter Neurosciences Price to Free Cash Flow Ratio 2023-2025 | JUNS

Jupiter Neurosciences price to free cash flow ratio from 2023 to 2025. Price to free cash flow ratio can be defined as

Jupiter Neurosciences Price to Free Cash Flow Ratio 2023-2025 | JUNS

Jupiter Neurosciences price to free cash flow ratio from 2023 to 2025. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$75.5B
Zoetis (ZTS)$67.5B
Takeda Pharmaceutical (TAK)$46.8B
Daiichi Sankyo, - (DSNKY)$44.2B
BeOne Medicines - (ONC)$30.6B
Sandoz Group AG (SDZNY)$24.9B
Summit Therapeutics (SMMT)$21B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.2B
Stevanato Group S.p.A (STVN)$7.7B
Corcept Therapeutics (CORT)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.7B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.8B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.3B
Hypermarcas (HYPMY)$3.2B
Crinetics Pharmaceuticals (CRNX)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.3B
Centessa Pharmaceuticals (CNTA)$2.1B
BioCryst Pharmaceuticals (BCRX)$1.8B
Ocular Therapeutix (OCUL)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B